RYTM

RHYTHM PHARMACEUTICALS, INC.

RYTM · CIK 1649904 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$190M
20182025
Net Income−$197M
20182025
Operating CF−$116M
20182025
Free Cash Flow−$117M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.2B$0.1B$0.1B————$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B$0.0B———
Gross Profit————————
R&D Expense$0.2B$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
SG&A Expense$0.2B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
Operating Income$-0.2B$-0.3B$-0.2B$-0.2B$-0.2B$-0.1B$-0.1B$-0.1B
Net Income$-0.2B$-0.3B$-0.2B$-0.2B$-0.1B$-0.1B$-0.0B$-0.0B
EPS (Basic)$-3.11$-4.34$-3.20$-3.47$-1.40———
EPS (Diluted)$-3.11$-4.34$-3.20$-3.47$-1.40———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.5B$0.4B$0.3B$0.4B$0.3B$0.2B$0.3B$0.3B
Current Assets$0.5B$0.4B$0.3B$0.4B$0.3B$0.2B$0.3B$0.3B
Cash & Equivalents$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B
Total Liabilities$0.2B$0.2B$0.2B$0.1B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.0B$0.2B$0.3B$0.3B$0.2B$0.3B$0.2B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B
Investing Cash Flow$-0.1B$-0.0B$-0.0B$0.0B$-0.1B$0.2B$-0.0B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.2B$0.2B$0.1B$0.2B$0.2B$0.0B$0.2B$0.2B
← Companies